Stay updated on Rucaparib in Platinum-Sensitive Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Rucaparib in Platinum-Sensitive Ovarian Cancer Clinical Trial page.

Latest updates to the Rucaparib in Platinum-Sensitive Ovarian Cancer Clinical Trial page
- Check5 days agoChange DetectedThe displayed site revision changed from v3.8.0 to v3.8.1, with the clinical trial record otherwise unchanged.SummaryDifference0.0%

- Check12 days agoChange DetectedThe page now presents the full ARIEL2 study record for rucaparib in patients with platinum-sensitive, relapsed ovarian, fallopian tube, or primary peritoneal cancer, including study details, eligibility criteria, outcomes, and participating locations.SummaryDifference89%

- Check19 days agoChange DetectedThe footer identifies the site revision as v3.8.0 instead of v3.7.2; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check33 days agoChange DetectedA sitewide banner announces an NIH terminology transition from “Artificial Intelligence” to “Super Intelligence.” The site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check47 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study page now shows a 403 Forbidden error instead of the ARIEL2 trial details, and the related study content has been removed, leaving only the error message.SummaryDifference18%

Stay in the know with updates to Rucaparib in Platinum-Sensitive Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rucaparib in Platinum-Sensitive Ovarian Cancer Clinical Trial page.